Gastrointestinal dysfunction in Parkinson's disease

The Lancet Neurology

Volumn 14, Issue 6, 2015, Pages 625-639

  Fasano, Alfonso ^a   Visanji, Naomi P ^a   Liu, Louis W C ^a   Lang, Antony E ^a   Pfeiffer, Ronald F ^b  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ANTIPARKINSON AGENT;

ALGORITHM; BACTERIAL OVERGROWTH; CONSTIPATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE COURSE; DYSPHAGIA; EVIDENCE BASED PRACTICE; GASTROINTESTINAL MOTILITY DISORDER; HELICOBACTER INFECTION; HUMAN; HYPERSALIVATION; INTESTINE FLORA; MALNUTRITION; META ANALYSIS; MULTICENTER STUDY (TOPIC); NEUROPROTECTION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH PARESIS; SWALLOWING; SYSTEMATIC REVIEW; TASTE DISORDER; TOOTH DISEASE; TREATMENT PLANNING; COMORBIDITY; COMPLICATION; GASTROINTESTINAL DISEASES;

COMORBIDITY; GASTROINTESTINAL DISEASES; HUMANS; PARKINSON DISEASE;

EID: 84929308938     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00007-1     Document Type: Review

References (173)

1. Pfeiffer RF Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003, 2:107-116.
2. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010, 119:689-702.
3. Gold A, Turkalp ZT, Munoz DG Enteric alpha-synuclein expression is increased in Parkinson's disease but not Alzheimer's disease. Movement Disord 2013, 28:237-240.
4. Bottner M, Zorenkov D, Hellwig I, et al. Expression pattern and localization of alpha-synuclein in the human enteric nervous system. Neurobiol Dis 2012, 48:474-480.
5. Braak H, Rub U, Gai WP, Del Tredici K Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003, 110:517-536.
6. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol 1988, 76:217-221.
7. Gray MT, Munoz DG, Gray DA, Schlossmacher MG, Woulfe JM Alpha-synuclein in the appendiceal mucosa of neurologically intact subjects. Mov Disord 2014, 29:991-998.
8. Beach TG, Adler CH, Dugger BN, et al. Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol 2013, 72:130-136.
9. Adler CH, Dugger BN, Hinni ML, et al. Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology 2014, 82:858-864.
10. Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PloS One 2010, 5:e12728.
11. Visanji NP, Marras C, Kern DS, et al. Colonic mucosal alpha-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology 2015, 84:609-616.
12. Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Movement Disord 2012, 27:709-715.
13. Visanji NP, Marras C, Hazrati LN, Liu LW, Lang AE Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord 2014, 29:444-450.
14. Visanji NP, Brooks PL, Hazrati LN, Lang AE The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathol Commun 2013, 1:2.
15. Gray MT, Munoz DG, Gray DA, Schlossmacher MG, Woulfe JM α-synuclein in the appendiceal mucosa of neurologically intact subjects. Mov Disord 2014, 29:991. 983.
16. Cersosimo M, Benarroch E Pathological correlates of gastrointestinal dysfunction in Parkinson's disease. Neurobiol Dis 2012, 46:559-564.
17. Pfeiffer RF Parkinson's disease and the gut: 'the wheel is come full circle'. J Parkinsons Dis 2014, 4:577-578.
18. Noorian AR, Rha J, Annerino DM, Bernhard D, Taylor GM, Greene JG Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system. Neurobiol Dis 2012, 48:9-19.
19. Muller T, Palluch R, Jackowski J Caries and periodontal disease in patients with Parkinson's disease. Spec Care Dentist 2011, 31:178-181.
20. Bakke M, Larsen SL, Lautrup C, Karlsborg M Orofacial function and oral health in patients with Parkinson's disease. Eur J Oral Sci 2011, 119:27-32.
21. Hanaoka A, Kashihara K Increased frequencies of caries, periodontal disease and tooth loss in patients with Parkinson's disease. J Clin Neurosci 2009, 16:1279-1282.
22. Srivanitchapoom P, Pandey S, Hallett M Drooling in Parkinson's disease: a review. Parkinsonism Relat Disord 2014, 20:1109-1118.
23. Nobrega AC, Rodrigues B, Melo A Is silent aspiration a risk factor for respiratory infection in Parkinson's disease patients?. Parkinsonism Relat Disord 2008, 14:646-648.
24. Eadie MJ, Tyrer JH Alimentary disorder in Parkinsonism. Austral Ann Med 1965, 14:13-22.
25. Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M Gastrointestinal symptoms in Parkinson's disease. Mov Disord 1991, 6:151-156.
26. Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF Characterization of swallowing and defecation in Parkinson's disease. Am J Gastroenterol 1994, 89:15-25.
27. Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF Autonomic dysfunction in Parkinson's disease: a comprehensive symptom survey. Parkinsonism Relat Disord 2002, 8:277-284.
28. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ Patient-reported autonomic symptoms in Parkinson disease. Neurology 2007, 69:333-341.
29. Nicaretta DH, de Rosso AL, Maliska C, Costa MM Scintigraphic analysis of the parotid glands in patients with sialorrhea and Parkinson's disease. Parkinsonism Relat Disord 2008, 14:338-341.
30. Kim HJ, Park SY, Cho YJ, et al. Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci 2009, 287:200-204.
31. Leibner J, Ramjit A, Sedig L, et al. The impact of and the factors associated with drooling in Parkinson's disease. Parkinsonism Relat Disord 2010, 16:475-477.
32. Yu B, Xiao ZY, Li JZ, Yuan J, Liu YM Study of an integrated non-motor symptoms questionnaire for Parkinson's disease. Chin Med J 2010, 123:1436-1440.
33. Muller B, Larsen JP, Wentzel-Larsen T, Skeie GO, Tysnes OB Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: frequent but mild. Mov Disord 2011, 26:65-72.
34. Damian A, Adler CH, Hentz JG, et al. Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease. Parkinsonism Relat Disord 2012, 18:1089-1093.
35. Picillo M, Amboni M, Erro R, et al. Gender differences in non-motor symptoms in early, drug naive Parkinson's disease. J Neurol 2013, 260:2849-2855.
36. Shah M, Deeb J, Fernando M, et al. Abnormality of taste and smell in Parkinson's disease. Parkinsonism Relat Disord 2009, 15:232-237.
37. Deeb J, Shah M, Muhammed N, et al. A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson's disease. QJM 2010, 103:941-952.
38. Kashihara K, Hanaoka A, Imamura T Frequency and characteristics of taste impairment in patients with Parkinson's disease: results of a clinical interview. Intern Med 2011, 50:2311-2315.
39. Pont-Sunyer C, Hotter A, Gaig C, et al. The Onset of Nonmotor Symptoms in Parkinson's disease (The ONSET PD Study). Mov Disord 2014, 30:229-237.
40. Clarke CE, Gullaksen E, Macdonald S, Lowe F Referral criteria for speech and language therapy assessment of dysphagia caused by idiopathic Parkinson's disease. Acta Neurol Scand 1998, 97:27-35.
41. Singer C, Weiner WJ, Sanchez-Ramos JR Autonomic dysfunction in men with Parkinson's disease. Eur Neurol 1992, 32:134-140.
42. Wang SJ, Fuh JL, Shan DE, et al. Sympathetic skin response and R-R interval variation in Parkinson's disease. Mov Disord 1993, 8:151-157.
43. Gonera EG, van't Hof M, Berger HJ, van Weel C, Horstink MW Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord 1997, 12:871-876.
44. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001, 57:456-462.
45. Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time and rectoanal videomanometry in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003, 74:268-272.
46. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006, 21:916-923.
47. Kaye J, Gage H, Kimber A, Storey L, Trend P Excess burden of constipation in Parkinson's disease: a pilot study. Mov Disord 2006, 21:1270-1273.
48. Krogh K, Ostergaard K, Sabroe S, Laurberg S Clinical aspects of bowel symptoms in Parkinson's disease. Acta Neurol Scand 2008, 117:60-64.
49. Savica R, Carlin JM, Grossardt BR, et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009, 73:1752-1758.
50. Ramjit AL, Sedig L, Leibner J, et al. The relationship between anosmia, constipation, and orthostasis and Parkinson's disease duration: results of a pilot study. Int J Neurosci 2010, 120:67-70.
51. Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D The patients' perception of prodromal symptoms before the initial diagnosis of Parkinson's disease. Mov Disord 2011, 26:653-658.
52. Szewczyk-Krolikowski K, Tomlinson P, Nithi K, et al. The influence of age and gender on motor and non-motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism Relat Disord 2014, 20:99-105.
53. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol 2015, 14:57-64.
54. Rana AQ, Yousuf MS, Awan N, Fattah A Impact of progression of Parkinson's disease on drooling in various ethnic groups. Eur Neurol 2012, 67:312-314.
55. Kalf JG, Munneke M, van den Engel-Hoek L, et al. Pathophysiology of diurnal drooling in Parkinson's disease. Mov Disord 2011, 26:1670-1676.
56. Kalf JG, Smit AM, Bloem BR, Zwarts MJ, Munneke M Impact of drooling in Parkinson's disease. J Neurol 2007, 254:1227-1232.
57. Cersosimo MG, Raina GB, Calandra CR, et al. Dry mouth: an overlooked autonomic symptom of Parkinson's disease. J Parkinsons Dis 2011, 1:169-173.
58. Cecchini MP, Osculati F, Ottaviani S, Boschi F, Fasano A, Tinazzi M Taste performance in Parkinson's disease. J Neural Transm 2014, 121:119-122.
59. Coon EA, Laughlin RS Burning mouth syndrome in Parkinson's disease: dopamine as cure or cause?. J Headache Pain 2012, 13:255-257.
60. Kalf JG, de Swart BJ, Bloem BR, Munneke M Prevalence of oropharyngeal dysphagia in Parkinson's disease: a meta-analysis. Parkinsonism Relat Disord 2012, 18:311-315.
61. Lin CW, Chang YC, Chen WS, Chang K, Chang HY, Wang TG Prolonged swallowing time in dysphagic Parkinsonism patients with aspiration pneumonia. Archs Phys Med Rehabil 2012, 93:2080-2084.
62. Pfeiffer RF Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2011, 17:10-15.
63. Noyce AJ, Silveira-Moriyama L, Gilpin P, Ling H, Howard R, Lees AJ Severe dysphagia as a presentation of Parkinson's disease. Mov Disord 2012, 27:457-458.
64. Kikuchi A, Baba T, Hasegawa T, et al. Hypometabolism in the supplementary and anterior cingulate cortices is related to dysphagia in Parkinson's disease: a cross-sectional and 3-year longitudinal cohort study. BMJ open 2013, 3:e002249.
65. Mu L, Sobotka S, Chen J, et al. Altered pharyngeal muscles in Parkinson disease. J Neuropathol Exper Neur 2012, 71:520-530.
66. Sheard JM, Ash S, Silburn PA, Kerr GK Prevalence of malnutrition in Parkinson's disease: a systematic review. Nutr Rev 2011, 69:520-532.
67. Fereshtehnejad SM, Ghazi L, Shafieesabet M, Shahidi GA, Delbari A, Lokk J Motor, psychiatric and fatigue features associated with nutritional status and its effects on quality of life in Parkinson's disease patients. PloS One 2014, 9:e91153.
68. Barichella M, Cereda E, Pezzoli G Major nutritional issues in the management of Parkinson's disease. Mov Disord 2009, 24:1881-1892.
69. Kistner A, Lhommee E, Krack P Mechanisms of body weight fluctuations in Parkinson's disease. Front Neurol 2014, 5:84.
70. Laudisio A, Vetrano DL, Meloni E, et al. Dopaminergic agents and nutritional status in Parkinson's disease. Mov Disord 2014, 29:1543-1547.
71. Adams F, Boschmann M, Lobsien E, et al. Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson's disease. Eur J Clin Pharmacol 2008, 64:863-870.
72. Ceravolo R, Cossu G, Bandettini di Poggio M, et al. Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. Mov Disord 2013, 28:1391-1397.
73. Sauleau P, Le Jeune F, Drapier S, et al. Weight gain following subthalamic nucleus deep brain stimulation: a PET study. Mov Disord 2014, 29:1781-1787.
74. Heetun ZS, Quigley EM Gastroparesis and Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2012, 18:433-440.
75. Goetze O, Nikodem AB, Wiezcorek J, et al. Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol Motil 2006, 18:369-375.
76. Parkman HP, Hasler WL, Fisher RS American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004, 127:1592-1622.
77. Zheng LF, Song J, Fan RF, et al. The role of the vagal pathway and gastric dopamine in the gastroparesis of rats after a 6-hydroxydopamine microinjection in the substantia nigra. Acta physiol (Oxf) 2014, 211:434-446.
78. Braak H, de Vos RA, Bohl JR, Del Tredici K Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006, 396:67-72.
79. Cheung CK, Wu JC Role of ghrelin in the pathophysiology of gastrointestinal disease. Gut Liver 2013, 7:505-512.
80. Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur J Neurol 2012, 19:864-869.
81. Dobbs RJ, Dobbs SM, Weller C, et al. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter 2005, 10:267-275.
82. Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013, 28:1241-1249.
83. Narozanska E, Bialecka M, Adamiak-Giera U, et al. Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection. Clin Neuropharmacol 2014, 37:96-99.
84. Tan AH, Mahadeva S, Thalha AM, et al. Small intestinal bacterial overgrowth in Parkinson's disease. Parkinsonism Relat Disord 2014, 20:535-540.
85. Isomoto H, Ueno H, Saenko VA, et al. Impact of Helicobacter pylori infection on gastric and plasma ghrelin dynamics in humans. Am J Gastroenterol 2005, 100:1711-1720.
86. Gabrielli M, Bonazzi P, Scarpellini E, et al. Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2011, 26:889-892.
87. Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee PL Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord 2008, 23:1696-1700.
88. Rahne KE, Tagesson C, Nyholm D Motor fluctuations and Helicobacter pylori in Parkinson's disease. J Neurol 2013, 260:2974-2980.
89. Pierantozzi M, Pietroiusti A, Brusa L, et al. Helicobacter pylori eradication andL-dopa absorption in patients with PD and motor fluctuations. Neurology 2006, 66:1824-1829.
90. Grace E, Shaw C, Whelan K, Andreyev HJ Review article: small intestinal bacterial overgrowth-prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 2013, 38:674-688.
91. Quigley EM, Quera R Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology 2006, 130:S78-S90.
92. Devos D, Lebouvier T, Lardeux B, et al. Colonic inflammation in Parkinson's disease. Neurobiol Dis 2013, 50:42-48.
93. Lomax AE, Linden DR, Mawe GM, Sharkey KA Effects of gastrointestinal inflammation on enteroendocrine cells and enteric neural reflex circuits. Auton Neurosci 2006, 126-127:250-257.
94. Scheperjans F, Aho V, Pereira PA, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 2014, 30:350-358.
95. Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PloS One 2011, 6:e28032.
96. Lin C, Lin J, Liu Y, Chang C, Wu R Risk of Parkinson's disease following severe constipation: a nationwide population-based cohort study. Parkinsonism Relat Disord 2014, 20:1371-1375.
97. Postuma RB, Gagnon JF, Pelletier A, Montplaisir J Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies. Mov Disord 2013, 28:597-604.
98. Wedel T, Spiegler J, Soellner S, et al. Enteric nerves and interstitial cells of Cajal are altered in patients with slow-transit constipation and megacolon. Gastroenterology 2002, 123:1459-1467.
99. Annerino DM, Arshad S, Taylor GM, Adler CH, Beach TG, Greene JG Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol 2012, 124:665-680.
100. Lebouvier T, Chaumette T, Damier P, et al. Pathological lesions in colonic biopsies during Parkinson's disease. Gut 2008, 57:1741-1743.
101. Jost WH Gastrointestinal dysfunction in Parkinson's Disease. J Neurol Sci 2010, 289:69-73.
102. Liu L Chronic constipation: current treatment options. Can J Gastroenterol 2011, 25:22B-28B.
103. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012, 61:646-664.
104. Peedikayil M, Alsohaibani F, Alkhenizan A Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. PloS One 2014, 9:e85620.
105. Martin-Harris B, Jones B The videofluorographic swallowing study. Phys MedRehabil Clin North Am 2008, 19:769-785. viii.
106. Sung HY, Kim JS, Lee KS, et al. The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson's disease. Mov Disord 2010, 25:2361-2368.
107. van Hooren MR, Baijens LW, Voskuilen S, Oosterloo M, Kremer B Treatment effects for dysphagia in Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2014, 20:800-807.
108. Camilleri M, Shin A Novel and validated approaches for gastric emptying scintigraphy in patients with suspected gastroparesis. Dig Dis Sci 2013, 58:1813-1815.
109. Bharucha AE, Pemberton JH, Locke GR American Gastroenterological Association technical review on constipation. Gastroenterology 2013, 144:218-238.
110. Packer M, Nikitin V, Coward T, Davis DM, Fiske J The potential benefits of dental implants on the oral health quality of life of people with Parkinson's disease. Gerodontology 2009, 26:11-18.
111. South AR, Somers SM, Jog MS Gum chewing improves swallow frequency and latency in Parkinson patients: a preliminary study. Neurology 2010, 74:1198-1202.
112. Arbouw ME, Movig KL, Koopmann M, et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology 2010, 74:1203-1207.
113. Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011, 26:S42-S80.
114. Hyson HC, Johnson AM, Jog MS Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002, 17:1318-1320.
115. Thomsen TR, Galpern WR, Asante A, Arenovich T, Fox SH Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord 2007, 22:2268-2273.
116. Lloret SP, Nano G, Carrosella A, Gamzu E, Merello M A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. J Neurol Sci 2011, 310:248-250.
117. Serrano-Duenas M Treatment of sialorrhea in Parkinson's disease patients with clonidine. Double-blind, comparative study with placebo. Neurologia 2003, 18:2-6. (in Spanish).
118. Kushnir M, Eilam A, Heldman E Modafinil reduces drooling in Parkinson's disease. Move Disord 2006, 21(suppl 13):S598-S599.
119. Jost WH Treatment of drooling in Parkinson's disease with botulinum toxin. Mov Disord 1999, 14:1057.
120. Pal PK, Calne DB, Calne S, Tsui JK Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000, 54:244-247.
121. Su CS, Lan MY, Liu JS, et al. Botulinum toxin type A treatment for Parkinsonian patients with moderate to severe sialorrhea. Acta Neurologica Taiwanica 2006, 15:170-176.
122. Santamato A, Ianieri G, Ranieri M, et al. Botulinum toxin type A in the treatment of sialorrhea in Parkinson's disease. J Am Geriatr Soc 2008, 56:765-767.
123. Friedman A, Potulska A Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkinsonism Relat Disord 2001, 7:329-332.
124. Dogu O, Apaydin D, Sevim S, Talas DU, Aral M Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004, 106:93-96.
125. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006, 21:704-707.
126. Guidubaldi A, Fasano A, Ialongo T, et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Mov Disord 2011, 26:313-319.
127. Nobrega AC, Rodrigues B, Torres AC, Enzo A, Melo A Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?. J Neurol Sci 2007, 253:85-87.
128. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003, 61:1279-1281.
129. Mancini F, Zangaglia R, Cristina S, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003, 18:685-688.
130. Racette BA, Good L, Sagitto S, Perlmutter JS Botulinum toxin B reduces sialorrhea in parkinsonism. Mov Disord 2003, 18:1059-1061.
131. Contarino MF, Pompili M, Tittoto P, et al. Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease. Parkinsonism Relat Disord 2007, 13:299-303.
132. Ondo WG, Hunter C, Moore W A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004, 62:37-40.
133. Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol 2009, 256:563-567.
134. Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. Mov Disord 2012, 27:219-226.
135. Menezes C, Melo A Does levodopa improve swallowing dysfunction in Parkinson's disease patients?. J Clin Pharm Ther 2009, 34:673-676.
136. Sutton JP Dysphagia in Parkinson's disease is responsive to levodopa. Parkinsonism Relat Disord 2013, 19:282-284.
137. Troche MS, Brandimore AE, Foote KD, Okun MS Swallowing and deep brain stimulation in Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2013, 19:783-788.
138. Sheard JM, Ash S, Mellick GD, Silburn PA, Kerr GK Markers of disease severity are associated with malnutrition in Parkinson's disease. PloS One 2013, 8:e57986.
139. Camilleri M, Parkman H, Shafi M, Abell T, Gerson L Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013, 108:18-37.
140. Larson JM, Tavakkoli A, Drane WE, Toskes PP, Moshiree B Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis. JNeurogastroenterol Motil 2010, 16:407-413.
141. Doi H, Sakakibara R, Sato M, et al. Nizatidine ameliorates gastroparesis in Parkinson's disease: a pilot study. Mov Disord 2014, 29:562-566.
142. McCallum RW, Lembo A, Esfandyari T, et al. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013, 25:e705-e717.
143. Bai Y, Xu MJ, Yang X, et al. A systematic review on intrapyloric botulinum toxin injection for gastroparesis. Digestion 2010, 81:27-34.
144. Arai E, Arai M, Uchiyama T, et al. Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease. Brain 2012, 135:1478-1485.
145. Jayanthi NV, Dexter SP, Sarela AI Gastric electrical stimulation for treatment of clinically severe gastroparesis. J Minim Access Surg 2013, 9:163-167.
146. Gatto M, Fernandez Pardal M, Melero M, Zurru C, Scorticati C, Micheli F L-dopa malabsorption in a parkinsonian patient with Strongyloides stercoralis duodenitis. Clin Neuropharmacol 1994, 17:96-98.
147. Yuan Y, Leontiadis G Levofloxacin-based three-antibiotic regimen for H. pylori eradication. Am J Gastroenterol 2012, 107:1106-1107.
148. Stahlmann R, Lode H Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging 2010, 27:193-209.
149. Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. AmJ Gastroenterol 2008, 103:2031-2035.
150. Eichhorn T, Oertel W Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord 2001, 16:1176-1177.
151. Ondo W, Kenney C, Sullivan K, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012, 78:1650-1654.
152. Lembo A, Johanson J, Parkman H, Rao S, Miner PJ, Ueno R Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci 2011, 56:2639-2645.
153. Sullivan K, Staffetti J, Hauser R, Dunne P, Zesiewicz T Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. Mov Disord 2006, 21:115-116.
154. Lembo A, Schneier H, Shiff S, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011, 365:527-536.
155. Albanese A, Maria G, Bentivoglio A, Brisinda G, Cassetta E, Tonali P Severe constipation in Parkinson's disease relieved by botulinum toxin. Mov Disord 1997, 12:764-766.
156. Ondo WG, Shinawi L, Moore S Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial. Mov Disord 2010, 25:2724-2727.
157. Stocchi F, Zappia M, Dall'Armi V, et al. Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. Mov Disord 2010, 25:1881-1887.
158. Jansson Y, Eriksson B, Johnels B Dispersible levodopa has a fast and more reproducible onset of action than the conventional preparation in Parkinson's disease. A study with optoelectronic movement analysis. Parkinsonism Relat Disord 1998, 4:201-206.
159. Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007, 22:2398-2404.
160. Pfeiffer RF, Gutmann L, Hull KL, et al. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism Relat Disord 2007, 13:93-100.
161. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013, 368:610-622.
162. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014, 13:141-149.
163. Fasano A, Bove F, Gabrielli M, et al. Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth. Clin Neuropharmacol 2014, 37:91-95.
164. Stocchi F, Fabbri L, Vecsei L, Krygowska-Wajs A, Monici Preti PA, Ruggieri SA Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clinical Neuropharmacol 2007, 30:18-24.
165. Fasano A, Ricciardi L, Lena F, Bentivoglio AR, Modugno N Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. Eur Rev Med Pharmacol Sci 2012, 16:79-89.
166. Frankel JP, Kempster PA, Bovingdon M, Webster R, Lees AJ, Stern GM The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry 1989, 52:1063-1067.
167. Ondo WG, Hunter C, Ferrara JM, Mostile G Apomorphine injections: predictors of initial common adverse events and long term tolerability. Parkinsonism Relat Disord 2012, 18:619-622.
168. Antonini A, Isaias IU, Rodolfi G, et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 2011, 258:579-585.
169. Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 2014, 85:840-844.
170. Fasano A, Daniele A, Albanese A Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol 2012, 11:429-442.
171. Iyer SS, Morgan JC, Sethi KD Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function. Neurology 2005, 65:1507.
172. Camilleri M, Acosta A Emerging treatments in Neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist. Neurogastroenterol Motil 2015, 27:324-332.
173. Aro P, Storskrubb T, Ronkainen J, et al. Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol 2006, 163:1025-1034.